Does Androgen-Deprivation Therapy Provide a Survival Benefit? A Look at Survival Outcomes in Men Receiving ADT as Primary or Salvage Treatment for Localized or Advanced Prostate Cancer- Conclusions from a 20-Year Single-Center Experience

The Department of Urology, University of Tennessee Health Science Center, Memphis, TN, performed a retrospective study designed to evaluate the overall survival (OS) and disease-specific survival (DSS) in men receiving primary androgen-deprivation therapy (PADT) or salvage medical ADT (SADT) for prostate cancer. The study included men who were diagnosed and treated with ADT between July [...]

Early Versus Deferred Androgen Suppression in the Treatment of Advanced Prostatic Cancer – Which Is Better?

An informative and comprehensive analysis of existing research studies evaluating the merits of early vs. deferred commencement of hormone therapy in men with advanced prostate cancer was recently published. The analysis (Wilt T, Nair B, MacDonald R, Rutks I. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database of Systematic [...]

Shorter Adjuvant Androgen-Deprivation Therapy for Prostate Cancer Leads to Reduced Survival

At the European Association of Urology’s 23rd Annual Congress there was an abstract presented (Abstract 186) that concluded that three-dimensional external beam radiation (EBRT) with 6 months of androgen deprivation therapy (ADT) for the treatment of patients with locally advanced prostate cancer shows significantly shorter patient survival than the same treatment followed by 3 years [...]

Go to Top